IDH1 and central nervous system cancer: Mutations have also been identified in isocitrate dehydrogenase 1 (IDH1) that inhibit IDH1 catalytic activity in glioma, thereby reducing the production of α-KG, increasing HIF-1α and presumably, tumorigenesis [14].